Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL11385 | 1.00 | MEN1 (0.54) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4953759 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL503887 | 0.95 | CYP4F2 (0.56) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1925892 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL8518463 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL6531912 | 0.95 | CYP4F2 (0.56) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1921958 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL8601641 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL717375 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL433597 | 0.95 | MEN1 (0.58) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| CN-101160306-B | Benzimidazole compounds | EISAI R&D MAN CO LTD | 2011-11-02 | — | — | CN | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | MIYAZAWA SHUHEI | 2009-08-13 | — | — | US | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| CN-101208302-A | Novel 4-aminopiperidine derivatives as plasmepsin ii inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-25 | — | — | CN | disclosed |
| CN-101160306-A | Benzimidazole compounds | EISAI R&D MAN CO LTD (JP) | 2008-04-09 | — | — | CN | disclosed |
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| EP-0858464-B1 | THROMBIN INHIBITORS | AKZO NOBEL NV (NL) | 2003-05-07 | — | — | EP | disclosed |
| US-6534495-B1 | Anticoagulants that prevent thrombin-related diseases. | AKZO NEBEL (NL) | 2003-03-18 | — | — | US | disclosed |
| US-20020142967-A1 | Thrombin inhibitors | ADANG A E P (NL) | 2002-10-03 | — | — | US | disclosed |
| US-6432921-B2 | OLIGOPEPTIDES | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-20010007764-A1 | THROMBIN INHIBITORS | N.V. ORGANON (NL) | 2001-07-12 | — | — | US | disclosed |
| EP-0979240-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 2000-02-16 | — | — | EP | disclosed |
| CN-1202902-A | Thrombin inhibitors | AKZO NOBEL NV (NL) | 1998-12-23 | — | — | CN | disclosed |
| WO-1998050420-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142967-A1 | Thrombin inhibitors | SERPINC1, DAO, CTRL | MEN1 4623/4885MAPT 4165/4885KMT2A 3042/4885 |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | HRH2, HRH4, HRH1 | MEN1 3215/4885MAPT 4704/4885KMT2A 3821/4885 |
| US-20010007764-A1 | THROMBIN INHIBITORS | SERPINC1, DAO, F2 | MEN1 3876/4885MAPT 3827/4885KMT2A 2263/4885 |
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | METAP1, DNPEP, PEPD | MEN1 1786/4885MAPT 3156/4885KMT2A 2973/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | MEN1 2954/4885MAPT 4733/4885KMT2A 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.